The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.
about
A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein AntigensRecent advances in pneumococcal peptidoglycan biosynthesis suggest new vaccine and antimicrobial targetsPanel 6: Vaccines.Monitoring the long-term molecular epidemiology of the pneumococcus and detection of potential 'vaccine escape' strains.Mapping of epitopes recognized by antibodies induced by immunization of mice with PspA and PspC.Host immunity in the protective response to nasal immunization with a pneumococcal antigen associated to live and heat-killed Lactobacillus casei.Salmonella vaccine vectors displaying delayed antigen synthesis in vivo to enhance immunogenicity.Development of Streptococcus pneumoniae Vaccines Using Live VectorsImmunization with a ZmpB-based protein vaccine could protect against pneumococcal diseases in mice.Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure.Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies.Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.Pneumococal Surface Protein A (PspA) Regulates Programmed Death Ligand 1 Expression on Dendritic Cells in a Toll-Like Receptor 2 and Calcium Dependent Manner.Generation and Improvement of Effector Function of a Novel Broadly Reactive and Protective Monoclonal Antibody against Pneumococcal Surface Protein A of Streptococcus pneumoniae.PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine.Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection.Impaired function of antibodies to pneumococcal surface protein A but not to capsular polysaccharide in Mexican American adults with type 2 diabetes mellitus.Discovery of Immunodominant B Cell Epitopes within Surface Pneumococcal Virulence Proteins in Pediatric Patients with Invasive Pneumococcal DiseaseA Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A.Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholineConjugation of polysaccharide 6B from Streptococcus pneumoniae with pneumococcal surface protein A: PspA conformation and its effect on the immune responseFree Sialic Acid Acts as a Signal That Promotes Streptococcus pneumoniae Invasion of Nasal Tissue and Nonhematogenous Invasion of the Central Nervous System.Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein AThe global distribution and diversity of protein vaccine candidate antigens in the highly virulent Streptococcus pnuemoniae serotype 1.Serotype-independent pneumococcal vaccines.Current status and perspectives on protein-based pneumococcal vaccines.Towards Identifying Protective B-Cell Epitopes: The PspA Story.Strategies to develop vaccines of pediatric interest.Pneumonia and Streptococcus pneumoniae vaccine.Immune response and protective efficacy of S9 ribosomal protein of Streptococcus pneumoniae in a model of sepsis.Pneumococcal PspA and PspC proteins: potential vaccine candidates for experimental otitis media.Evaluation of protective efficacy of selected immunodominant B-cell epitopes within virulent surface proteins of S. Pneumoniae.Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity.
P2860
Q26753152-B85E2CCF-D609-4A0F-8377-B5EE38C9FD02Q27009118-8F0F0DA8-C5D9-4776-AA92-93AFBCBB56EAQ33644678-A86B3DA3-B4C4-4495-AAD9-23C49F3A50E0Q33802910-5744E938-C65B-43E1-AD33-542566499006Q33899358-F00E0A74-973B-4AB2-B95C-6BF78D72302AQ33990842-7DF4B703-7E05-462B-9D09-6977C23CD498Q34119481-BF41B255-9CE6-4F49-8148-0321A495DD48Q34316015-83C9E131-C38D-4CC9-8077-467F531776ADQ34529480-E80B9DB2-346B-4845-8D7B-1906690132BDQ34591762-EC971D14-BAB9-4AA4-8E54-AEFFE20668C7Q34784957-EB2CB925-2983-4547-940E-EB0CF850F58DQ35021099-3A647368-03D7-48E1-A039-CA2E89B2323AQ35716191-660A093B-8D0E-4F9F-9A3A-F935DBF6F169Q36015321-0ADC381C-4A1F-48BC-993C-0AF238378C15Q36017785-B0FD3818-0F7D-4ADA-A571-E3BE21531EFDQ36087567-CAE7E27C-5FCD-43D1-8B5A-3A925C87701AQ36191655-7ACFBD44-8F9B-439F-A380-00987E5B47E8Q36282841-112EA0F4-0838-4423-B2A9-5C5034885461Q36409520-40F9E4F3-10B7-4429-B6EE-05C634DEFB35Q36454995-688981A7-FC24-48FD-BC89-1EAE8E99B1EEQ36911270-73E83E9D-A9CE-4519-BD85-3843B6C3DBBEQ37199889-A31C230E-D49B-46F8-AC1B-63A6D0094C41Q37252358-028CB4A7-A0AA-4AB2-B121-3AB445D8113EQ37619104-E3F30A74-D5EB-4EE3-A713-85AC9C3B800BQ38069943-DBA08912-143F-4458-BBB8-AE542D0F2649Q38124921-B86FE5CB-B625-4AEE-8A02-1A5F16B6BD66Q38781789-D3B8AAA8-720B-4B88-BFEB-B3E59983CFF7Q38819027-371151A1-AFBD-43E7-89BD-A7D8B1AB2736Q39452604-528B0D5A-1E9C-44E5-B462-62C683B0852DQ39566851-457E725A-89DC-4702-A0EA-F27863B88844Q42083281-3E38B887-E966-440E-BB18-C69EDE95E759Q47269510-7AAFB1E9-8AE7-4532-B56C-3D2C3D915B4CQ51732398-3E5F93CF-D91F-40C5-8F4A-DEDED0B557F6
P2860
The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
The proline-rich region of pne ...... ted protection against sepsis.
@en
type
label
The proline-rich region of pne ...... ted protection against sepsis.
@en
prefLabel
The proline-rich region of pne ...... ted protection against sepsis.
@en
P2093
P2860
P356
P1476
The proline-rich region of pne ...... ted protection against sepsis.
@en
P2093
Calvin C Daniels
David E Briles
Janice King
Joanetha Hale
Kimberly A Benton
Patricia Coan
Susan K Hollingshead
P2860
P304
P356
10.1128/IAI.01199-09
P407
P577
2010-03-01T00:00:00Z